Table 4 Risk of VTE according to HbA1c levels measured within 90 days prior to the index date (i.d.)
Number of cases (%) | Number of controls (%) | Unadjusted ORs (95% CI) | Adjusted ORs* (95% CI) | |
|---|---|---|---|---|
HbA1c level < 90 days prior to i.d. overall | ||||
≤ 6.5% | 278 (22.9) | 1345 (28.6) | 1.00 (0.81–1.23) | 1.04 (0.84–1.30) |
> 6.5–7.0% | 161 (13.3) | 789 (16.8) | 1 (reference) | 1 (reference) |
> 7.0–7.5% | 172 (14.2) | 616 (13.1) | 1.40 (1.10–1.78) | 1.44 (1.11–1.87) |
> 7.5–8.0% | 108 (8.9) | 380 (8.1) | 1.43 (1.10–1.88) | 1.46 (1.09–1.94) |
> 8.0–9.0% | 132 (10.9) | 394 (8.4) | 1.69 (1.30–2.19) | 1.64 (1.23–2.17) |
> 9.0% | 140 (11.5) | 460 (9.8) | 1.50 (1.17–1.92) | 1.32 (1.01–1.73) |
No Recording** | 222 (18.3) | 716 (15.2) | 1.75 (1.36–2.23) | 1.78 (1.38–2.31) |
HbA1c level < 90 days prior to i.d. in women | ||||
≤ 6.5% | 155 (11.0) | 746 (13.3) | 0.99 (0.74–1.34) | 1.03 (0.75–1.40) |
> 6.5–7.0% | 82 (5.8) | 417 (7.4) | 1 (reference) | 1 (reference) |
> 7.0–7.5% | 99 (7.0) | 335 (6.0) | 1.47 (1.05–2.06) | 1.55 (1.08–2.24) |
> 7.5–8.0% | 51 (3.6) | 192 (3.4) | 1.36 (0.92–2.01) | 1.43 (0.93–2.18) |
> 8.0–9.0% | 66 (4.7) | 208 (3.7) | 1.50 (1.04–2.15) | 1.36 (0.91–2.03) |
> 9.0% | 79 (5.6) | 239 (4.2) | 1.61 (1.13–2.29) | 1.47 (0.99–2.17) |
No Recording** | 876 (62.2) | 3495 (62.1) | 1.94 (1.39–2.71) | 1.98 (1.40–2.81) |
HbA1c level < 90 days prior to i.d. in men | ||||
≤ 6.5% | 125 (10.0) | 614 (12.3) | 1.00 (0.75–1.34) | 1.04 (0.76–1.43) |
> 6.5–7.0% | 81 (6.5) | 379 (7.6) | 1 (reference) | 1 (reference) |
> 7.0–7.5% | 76 (6.1) | 292 (5.9) | 1.32 (0.93–1.86) | 1.35 (0.91–1.99) |
> 7.5–8.0% | 58 (4.7) | 191 (3.8) | 1.50 (1.04–2.17) | 1.48 (0.99–2.22) |
> 8.0–9.0% | 67 (5.4) | 186 (3.7) | 1.93 (1.33–2.80) | 1.94 (1.28–2.96) |
> 9.0% | 62 (5.0) | 226 (4.5) | 1.37 (0.96–1.95) | 1.23 (0.83–1.82) |
No Recording** | 776 (62.3) | 3092 (62.1) | 1.50 (1.04–2.17) | 1.56 (1.04–2.34) |